A trial to test an antibody as an experimental treatment for Patients with Advanced or Metastatic Solid Tumors (VISTA)

Phase I dose escalation and dose expansion, international, multicenter study of W0180 as single agent and in combination with pembrolizumab (anti-PD-1) in adult participants with locally advanced or metastatic solid tumors.

Hide study title
Status
Status :
Recruiting
Type of study
Phase I
Min. Age
18
Years old
Max. Age
-
Gender
All

Brief summary

The objective of this trial is to evaluate the tolerance and the activity of an experimental treatment (called W0180), alone and in combination with an existing immunotherapy treatment (pembrolizumab) in patients with different advanced cancers (large local or distant spread of their tumor) excluding blood cancers.
This is the first time that this treatment (W0180) is tested in humans.
The trial includes 2 parts:
- The dose escalation part to determine the best-tolerated dose
- The dose expansion part to confirm the selected dose and provide additional information on tolerance and treatment activity

Therapeutic area :
Oncology
Disease :
Locally advanced or metastatic solid cancer tumors
Study medication :
Monoclonal antibody W0180
Phase : Phase I
Start Date :
08 September 2020
End Date / Planned study Completion Date :
May 2024
Study ID : W00180IV101
EudraCT/CTIS number : 2019-002299-15
CT.gov Number : NCT04564417
Countries :
France
Spain

Find out where the clinical trial is conducted

1

Clinica Universidad de Navarra - Sede Madrid

Calle Marquesado de Santa Marta, 1
28027 Madrid
Spain

2

Clinica Universidad de Navarra - Sed Navarra

Avenida Pio XII 36,
31008 Pamplona
Spain

3

Institut Claudius Regaud (IUCT-O)

1, avenue Irène Joliot Curie
31059 Toulouse
France

4

Gustave Roussy (IGR)

114, rue Edouard Vaillant
94805 Villejuif
France

Last update at : 15 November 2023

Contact Us

Need more information or are interested in enrolling in this study, click on the button to have access to the contact form.

Contact Us

Access to Lay Protocol Synopsis

Un résumé du protocole rédigé en termes simples et décrivant les objectifs de l’étude vous est proposé.  

Send by email